HUTCHMED (China) Limited (HCM) RNS Announcements

Add to Alert list
Date Time Source Announcement
31 Mar 2023 09:30 AM
RNS
Total Voting Rights
31 Mar 2023 07:00 AM
RNS
Rolling Submission of Fruquintinib US NDA Complete
14 Mar 2023 01:30 PM
RNS
Closing of Fruquintinib License to Takeda
08 Mar 2023 08:30 AM
RNS
Director's Share Dealing
06 Mar 2023 08:30 AM
RNS
Vesting of awards under the LTIP
28 Feb 2023 12:15 PM
RNS
Publication of Form 20-F
28 Feb 2023 08:30 AM
RNS
2022 Full Year Results and Business Updates
27 Feb 2023 10:00 AM
RNS
Enrollment Completed in Phase 2 Amdizalisib trial
31 Jan 2023 08:30 AM
RNS
Notice of Results
23 Jan 2023 08:00 AM
RNS
License to Takeda for Fruquintinib outside China
18 Jan 2023 02:30 PM
RNS
Inclusion of ORPATHYS in NRDL in China
03 Jan 2023 08:30 AM
RNS
Enrollment Completed in Phase 3 Trial
30 Dec 2022 08:30 AM
RNS
Blocklisting Six Monthly Return
19 Dec 2022 10:00 AM
RNS
FDA NDA Rolling Submission for Fruquintinib
15 Nov 2022 07:00 AM
RNS
HUTCHMED Announces Strategy Update
14 Nov 2022 07:00 AM
RNS
Positive Topline Phase 3 Result in Fruquintinib
27 Oct 2022 12:30 PM
RNS
HUTCHMED Initiates Phase 2/3 Trial of Fruquintinib
21 Oct 2022 09:30 AM
RNS
Vesting of awards under the LTIP
10 Oct 2022 09:30 AM
RNS
Phase II/III Trial of Sovleplenib for in China
30 Sep 2022 09:30 AM
RNS
Total Voting Rights
14 Sep 2022 11:00 AM
RNS
Share Option Scheme and Long Term Incentive Plan
08 Sep 2022 07:00 AM
RNS
FRESCO-2 Colorectal Cancer MRCT Data Highlights
23 Aug 2022 10:00 AM
RNS
Holding(s) in Company
23 Aug 2022 09:30 AM
RNS
HUTCHMED To Present FRESCO-2 Data at ESMO 2022
09 Aug 2022 09:30 AM
RNS
First Participant in Phase I Trial of IMG-004
08 Aug 2022 09:30 AM
RNS
Preliminary results from SAVANNAH Phase 2 Trial
08 Aug 2022 07:00 AM
RNS
FRESCO-2 Study Has Met Primary Endpoint
01 Aug 2022 12:04 PM
RNS
Interim Results and Business Updates
01 Aug 2022 07:00 AM
RNS
HUTCHMED Initiates Bridging Study of Tazemetostat
15 Jul 2022 09:30 AM
RNS
HUTCHMED Initiates Phase I Trial of HMPL-A83
13 Jul 2022 07:00 AM
RNS
Results of SAVANNAH Global Phase II Trial at WCLC
06 Jul 2022 07:00 AM
RNS
First Participants in Phase I Trial of IMG-007
30 Jun 2022 09:30 AM
RNS
Total Voting Rights
29 Jun 2022 09:30 AM
RNS
Blocklisting Six Monthly Return
27 Jun 2022 09:30 AM
RNS
HUTCHMED to Announce 2022 Half-Year Results
01 Jun 2022 09:30 AM
RNS
TAZVERIK® Approved in Hainan Pilot Zone
24 May 2022 11:00 AM
RNS
LTIP and Share Options
16 May 2022 12:00 PM
RNS
Appointment of Non-Executive Director
03 May 2022 07:00 AM
RNS
HUTCHMED Receives CRL from the US FDA
27 Apr 2022 02:30 PM
RNS
Annual General Meeting Poll Results
21 Apr 2022 09:30 AM
RNS
Vesting of awards under Long Term Incentive Plan
31 Mar 2022 07:00 AM
RNS
Update on Status under HFCAA
23 Mar 2022 08:30 AM
RNS
2021 Annual Report and Notice of AGM
11 Mar 2022 09:00 AM
RNS
Update on Status under HFCAA
09 Mar 2022 08:30 AM
RNS
Vesting of awards under Long Term Incentive Plan
07 Mar 2022 07:00 AM
RNS
HUTCHMED Receives $15m Milestone from AstraZeneca
03 Mar 2022 03:30 PM
RNS
Publication of Form 20-F
03 Mar 2022 12:30 PM
RNS
Retirement of CEO and appointment of new CEO
03 Mar 2022 12:00 PM
RNS
Full Year Results and Business Updates
01 Mar 2022 08:30 AM
RNS
Approval to Commercialize ELUNATE® in Macau

Hutchmed China  Limited develops, manufactures, and sells pharmaceutical products. The Company offers drugs for oncology and autoimmune diseases treatment. HUTCHMED (China) is headquartered in Hong Kong and markets its products worldwide.

It was founded in 2000 and listed in London in 2018 under the ticker HCM. 

UK 100